Cardio3Biosciences opens a new manufacturing facility in Rochester (United States). #belgium #usa #biotech
Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), from Mont-Saint-Guibert (Belgium), a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company’s current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure® (CHART-2), and its recently acquired CAR T-cell therapies’ portfolio. The facility will also serve as a base for the Company’s research and clinical collaboration with Mayo Clinic, also based in Rochester.